Statin induced myopathy screening
Jump to navigation
Jump to search
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby
Statin induced myopathy Microchapters |
Diagnosis |
---|
Treatment |
Statin induced myopathy screening On the Web |
American Roentgen Ray Society Images of Statin induced myopathy screening |
Risk calculators and risk factors for Statin induced myopathy screening |
Overview
Screening by the measurement of the creatine kinase level is not recommended by the national lipid association for statin induced myopathy unless the patient has significant predisposing factors like renal diseases, thyroid problems, metabolic diseases or pre-existing muscular diseases.[1]
Screening
- The American Heart Association and the National Heart, Lung, and. Blood Institute (AHA/NHLBI) statin clinical advisory panel recommends the measurement of the creatine kinase level before the initiation of statin therapy.
- The national lipid association does not recommend the measurement of the creatine kinase level before the initiation of statin therapy for all patients. It is useful to check the creatine level in patients with high risk factors for statin induced myopathy as for example patient with kidney diseases.
- Otherwise, the level of creatine kinase should be measured only in the presence of symptoms of muscle pain, tenderness or pain[1]
References
- ↑ 1.0 1.1 Harper CR, Jacobson TA (2010). "Evidence-based management of statin myopathy". Curr Atheroscler Rep. 12 (5): 322–30. doi:10.1007/s11883-010-0120-9. PMID 20628837.